144 related articles for article (PubMed ID: 37148799)
1. Identifying trajectories of symptom change in adults with obsessive compulsive disorder receiving exposure and response prevention therapy.
Kim H; Wheaton MG; Foa EB; Simpson HB
J Anxiety Disord; 2023 May; 96():102711. PubMed ID: 37148799
[TBL] [Abstract][Full Text] [Related]
2. Distinct trajectories of long-term symptom severity in pediatric obsessive-compulsive disorder during and after stepped-care treatment.
Jensen S; Højgaard DRMA; Hybel KA; Mortensen EL; Skarphedinsson G; Melin K; Ivarsson T; Nissen JB; Weidle B; Valderhaug R; Torp NC; Dahl K; Compton S; Thomsen PH
J Child Psychol Psychiatry; 2020 Sep; 61(9):969-978. PubMed ID: 31736082
[TBL] [Abstract][Full Text] [Related]
3. Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.
Wheaton MG; Gershkovich M; Gallagher T; Foa EB; Simpson HB
Depress Anxiety; 2018 Mar; 35(3):256-263. PubMed ID: 29394511
[TBL] [Abstract][Full Text] [Related]
4. The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.
Williams MT; Farris SG; Turkheimer EN; Franklin ME; Simpson HB; Liebowitz M; Foa EB
J Anxiety Disord; 2014 Aug; 28(6):553-8. PubMed ID: 24983796
[TBL] [Abstract][Full Text] [Related]
5. Obsessive compulsive personality disorder as a predictor of exposure and ritual prevention outcome for obsessive compulsive disorder.
Pinto A; Liebowitz MR; Foa EB; Simpson HB
Behav Res Ther; 2011 Aug; 49(8):453-8. PubMed ID: 21600563
[TBL] [Abstract][Full Text] [Related]
6. Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.
Zandberg LJ; Zang Y; McLean CP; Yeh R; Simpson HB; Foa EB
Behav Res Ther; 2015 May; 68():76-81. PubMed ID: 25824533
[TBL] [Abstract][Full Text] [Related]
7. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
[TBL] [Abstract][Full Text] [Related]
8. Response versus remission in obsessive-compulsive disorder.
Simpson HB; Huppert JD; Petkova E; Foa EB; Liebowitz MR
J Clin Psychiatry; 2006 Feb; 67(2):269-76. PubMed ID: 16566623
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.
Foa EB; Simpson HB; Gallagher T; Wheaton MG; Gershkovich M; Schmidt AB; Huppert JD; Imms P; Campeas RB; Cahill S; DiChiara C; Tsao SD; Puliafico A; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanches-LaCay A; Capaldi S; Snorrason Í; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hamlett GE; Middleton R; Hahn CG; Xu B; Van Meter PE; Katechis M; Rosenfield D
JAMA Psychiatry; 2022 Mar; 79(3):193-200. PubMed ID: 35080598
[TBL] [Abstract][Full Text] [Related]
10. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
[TBL] [Abstract][Full Text] [Related]
11. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder.
Simpson HB; Liebowitz MR; Foa EB; Kozak MJ; Schmidt AB; Rowan V; Petkova E; Kjernisted K; Huppert JD; Franklin ME; Davies SO; Campeas R
Depress Anxiety; 2004; 19(4):225-33. PubMed ID: 15274171
[TBL] [Abstract][Full Text] [Related]
12. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
13. Does the addition of cognitive therapy to exposure and response prevention for obsessive compulsive disorder enhance clinical efficacy? A randomized controlled trial in a community setting.
Rector NA; Richter MA; Katz D; Leybman M
Br J Clin Psychol; 2019 Mar; 58(1):1-18. PubMed ID: 29984550
[TBL] [Abstract][Full Text] [Related]
14. Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder.
Simpson HB; Maher MJ; Wang Y; Bao Y; Foa EB; Franklin M
J Consult Clin Psychol; 2011 Apr; 79(2):247-252. PubMed ID: 21355639
[TBL] [Abstract][Full Text] [Related]
15. Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder.
Simpson HB; Zuckoff AM; Maher MJ; Page JR; Franklin ME; Foa EB; Schmidt AB; Wang Y
Behav Res Ther; 2010 Oct; 48(10):941-8. PubMed ID: 20609435
[TBL] [Abstract][Full Text] [Related]
16. Online Video Teletherapy Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention: Clinical Outcomes From a Retrospective Longitudinal Observational Study.
Feusner JD; Farrell NR; Kreyling J; McGrath PB; Rhode A; Faneuff T; Lonsway S; Mohideen R; Jurich JE; Trusky L; Smith SM
J Med Internet Res; 2022 May; 24(5):e36431. PubMed ID: 35587365
[TBL] [Abstract][Full Text] [Related]
17. Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.
Simpson HB; Foa EB; Wheaton MG; Gallagher T; Gershkovich M; Schmidt AB; Huppert JD; Campeas RB; Imms PA; Cahill SP; DiChiara C; Tsao SD; Puliafico AC; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanchez-LaCay A; Capaldi S; Snorrason I; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hahn CG; Xu B; Van Meter PE; Katechis M; Scodes J; Wang Y
Behav Res Ther; 2021 Aug; 143():103890. PubMed ID: 34089924
[TBL] [Abstract][Full Text] [Related]
18. Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder.
Pagliaccio D; Middleton R; Hezel D; Steinman S; Snorrason I; Gershkovich M; Campeas R; Pinto A; Van Meter P; Simpson HB; Marsh R
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20346-20353. PubMed ID: 31548396
[TBL] [Abstract][Full Text] [Related]
19. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
Wheaton MG; Rosenfield D; Foa EB; Simpson HB
J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
[TBL] [Abstract][Full Text] [Related]
20. The effect of treatment on quality of life and functioning in OCD.
Asnaani A; Kaczkurkin AN; Alpert E; McLean CP; Simpson HB; Foa EB
Compr Psychiatry; 2017 Feb; 73():7-14. PubMed ID: 27838572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
